Particularly, Crenigacestat was able to selectively inhibit NOTCH1 in vitro and in the PDX model, reducing tumor progression by blocking new vessel formation in the surrounding desmoplastic reaction tissue. The gene discussed is NOTCH1; the disease is neoplasm.